Puromycin | CAS#53-79-2 | Protein Synthesis inhibitor

MedKoo Cat#: 571550 | Name: Puromycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Puromycin is an antibiotic protein synthesis inhibitor which causes premature chain termination during translation. Puromycin is a cinnamamido ADENOSINE found in STREPTOMYCES alboniger. Puromycin inhibits protein synthesis by binding to RNA. Puromycin is an antineoplastic and antitrypanosomal agent and is used in research as an inhibitor of protein synthesis. Puromycin also serves an an anticancer drug by supressing the growth and metastasis in esophagus cancer cells by Akt phosphorylation.

Chemical Structure

Puromycin

CAS#53-79-2 (free base)

Theoretical Analysis

MedKoo Cat#: 571550

Name: Puromycin

CAS#: 53-79-2 (free base)

Chemical Formula: C22H29N7O5

Exact Mass: 471.2230

Molecular Weight: 471.52

Elemental Analysis: C, 56.04; H, 6.20; N, 20.79; O, 16.97

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,850.00	2 Weeks
2g	USD 6,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

53-79-2 (free base) 58-58-2 (2HCl) 3506-23-8 (HCl)

Synonym

Puromycin; Puromycine; NSC-3055; NSC3055; NSC 3055

IUPAC/Chemical Name

Adenosine, 3'-(((2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyl-

InChi Key

RXWNCPJZOCPEPQ-NVWDDTSBSA-N

InChi Code

InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1

SMILES Code

OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C(N=CN=C43)N(C)C)O1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Puromycin inhibits protein synthesis by binding to RNA. It is an antineoplastic and antitrypanosomal agent and is used in research as an inhibitor of protein synthesis. It also serves an an anticancer drug by suppressing the growth and metastasis in esophagus cancer cells by Akt phosphorylation.

In vitro activity:

The effects of Puromycin aminonucleoside (PAN) were investigated on podocytes in the context of diabetic nephropathy. PAN treatment had a dose- and time-dependent inhibitory effect on podocyte proliferation, suggesting its role in suppressing cell growth. KLF5 overexpression induced cell cycle arrest in podocytes when regulated by PAN. KLF5 overexpression was shown to inhibit PAN-induced apoptosis of podocyte. Reference: Mol Med Rep. 2018 Oct;18(4):3843-3849. https://pubmed.ncbi.nlm.nih.gov/30106142/

In vivo activity:

In adult zebrafish, puromycin administration led to kidney injury, causing rapid clearance of substances from the kidney and resulting in morphological changes in the kidney structure, which recovered over time. During the process of nephron injury and regeneration, various molecular markers associated with kidney injury and repair showed significant changes, including increased expression of renal progenitor marker lhx1a and upregulation of NFκB, TNFα, Nampt, and p-ERK. Reference: Anim Cells Syst (Seoul). 2023 Apr 20;27(1):112-119. https://pubmed.ncbi.nlm.nih.gov/37089626/

Preparing Stock Solutions

The following data is based on the product molecular weight 471.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Li Y, Sui X, Hu X, Hu Z. Overexpression of KLF5 inhibits puromycin‑induced apoptosis of podocytes. Mol Med Rep. 2018 Oct;18(4):3843-3849. doi: 10.3892/mmr.2018.9366. Epub 2018 Aug 9. PMID: 30106142; PMCID: PMC6131625. 2. Hernández-Damián J, Tecalco-Cruz AC, Ríos-López DG, Vázquez-Victorio G, Vázquez-Macías A, Caligaris C, Sosa-Garrocho M, Flores-Pérez B, Romero-Avila M, Macías-Silva M. Downregulation of SnoN oncoprotein induced by antibiotics anisomycin and puromycin positively regulates transforming growth factor-β signals. Biochim Biophys Acta. 2013 Nov;1830(11):5049-58. doi: 10.1016/j.bbagen.2013.07.006. Epub 2013 Jul 18. PMID: 23872350. 3. Koun S, Park HJ, Jung SM, Cha JJ, Cha DR, Kang YS. Puromycin-induced kidney injury and subsequent regeneration in adult zebrafish. Anim Cells Syst (Seoul). 2023 Apr 20;27(1):112-119. doi: 10.1080/19768354.2023.2203211. PMID: 37089626; PMCID: PMC10120544. 4. Sakamoto H, Hirakawa Y, Ishida KI, Keeling PJ, Kita K, Matsuzaki M. Puromycin selection for stable transfectants of the oyster-infecting parasite Perkinsus marinus. Parasitol Int. 2019 Apr;69:13-16. doi: 10.1016/j.parint.2018.10.011. Epub 2018 Oct 30. PMID: 30389616.

In vitro protocol:

In vivo protocol:

1. Koun S, Park HJ, Jung SM, Cha JJ, Cha DR, Kang YS. Puromycin-induced kidney injury and subsequent regeneration in adult zebrafish. Anim Cells Syst (Seoul). 2023 Apr 20;27(1):112-119. doi: 10.1080/19768354.2023.2203211. PMID: 37089626; PMCID: PMC10120544. 2. Sakamoto H, Hirakawa Y, Ishida KI, Keeling PJ, Kita K, Matsuzaki M. Puromycin selection for stable transfectants of the oyster-infecting parasite Perkinsus marinus. Parasitol Int. 2019 Apr;69:13-16. doi: 10.1016/j.parint.2018.10.011. Epub 2018 Oct 30. PMID: 30389616.

1: Gómez-Morón Á, Tsukalov I, Scagnetti C, Pertusa C, Lozano-Prieto M, Martínez- Fleta P, Requena S, Martín P, Alfranca A, Martin-Gayo E, Martin-Cofreces NB. Cytosolic protein translation regulates cell asymmetry and function in early TCR activation of human CD8+ T lymphocytes. Front Immunol. 2024 Jul 24;15:1411957. doi: 10.3389/fimmu.2024.1411957. PMID: 39114656; PMCID: PMC11303187. 2: Yousef M, Bou-Chacra N, Löbenberg R, Davies NM. Understanding lymphatic drug delivery through chylomicron blockade: A retrospective and prospective analysis. J Pharmacol Toxicol Methods. 2024 Aug 2:107548. doi: 10.1016/j.vascn.2024.107548. Epub ahead of print. PMID: 39098619. 3: Gao Y, Kwan J, Orofino J, Burrone G, Mitra S, Fan TY, English J, Hekman R, Emili A, Lyons SM, Cardamone MD, Perissi V. Inhibition of K63 ubiquitination by G-Protein pathway suppressor 2 (GPS2) regulates mitochondria-associated translation. Pharmacol Res. 2024 Jul 31;207:107336. doi: 10.1016/j.phrs.2024.107336. Epub ahead of print. PMID: 39094987. 4: Chan SW. CRISPR-editing of the virus vector Aedes albopictus cell line C6/36, illustrated by prohibitin 2 gene knockout. MethodsX. 2024 Jun 21;13:102817. doi: 10.1016/j.mex.2024.102817. PMID: 39049926; PMCID: PMC11267050. 5: Juncos LI, Adeoye AO, Martin FL, Juncos JP, Baigorria ST, García NH. Angiotensin II-independent abnormal renal vascular reactivity during puromycin nephropathy. J Med Life. 2024 Mar;17(3):309-313. doi: 10.25122/jml-2023-0367. PMID: 39044930; PMCID: PMC11262600. 6: Wang J, Feng L, Zhang Y, Xu P. [Establishment of a stable THP-1 cell line expressing PSMB9-eGFP-His protein and detection of immunoproteasome activity]. Sheng Wu Gong Cheng Xue Bao. 2024 Jul 25;40(7):2282-2293. Chinese. doi: 10.13345/j.cjb.240124. PMID: 39044591. 7: Brischigliaro M, Krüger A, Moran JC, Antonicka H, Ahn A, Shoubridge EA, Rorbach J, Barrientos A. The human mitochondrial translation factor TACO1 alleviates mitoribosome stalling at polyproline stretches. Nucleic Acids Res. 2024 Jul 22:gkae645. doi: 10.1093/nar/gkae645. Epub ahead of print. PMID: 39036954. 8: Tripathi M, Gauthier K, Sandireddy R, Zhou J, Guptta P, Sakthivel S, Teo WW, Naing YT, Arul K, Tikno K, Park SH, Wu Y, Wang L, Bay BH, Sun L, Giguere V, Chow PKH, Ghosh S, McDonnell DP, Yen PM, Singh BK. Esrra regulates Rplp1-mediated translation of lysosome proteins suppressed in metabolic dysfunction-associated steatohepatitis and reversed by alternate day fasting. Mol Metab. 2024 Sep;87:101997. doi: 10.1016/j.molmet.2024.101997. Epub 2024 Jul 19. PMID: 39032642. 9: Lenser M, Ngo HG, Sarrafha L, Rajendra Y. Evaluation of two transposases for improving expression of recombinant proteins in Chinese hamster ovary cell stable pools by co-transfection and supertransfection approaches. Biotechnol Prog. 2024 Jul 17:e3496. doi: 10.1002/btpr.3496. Epub ahead of print. PMID: 39016635. 10: Kim J, Park S, Kim SJ, Yoo I, Kim H, Hwang S, Sim KM, Kim I, Jun E. High- throughput drug screening using a library of antibiotics targeting cancer cell lines that are resistant and sensitive to gemcitabine. Biochem Biophys Res Commun. 2024 Jul 7;730:150369. doi: 10.1016/j.bbrc.2024.150369. Epub ahead of print. PMID: 39013264. 11: Scarpitti MR, Pastore B, Tang W, Kearse MG. Characterization of ribosome stalling and no-go mRNA decay stimulated by the fragile X protein, FMRP. J Biol Chem. 2024 Jul 4;300(8):107540. doi: 10.1016/j.jbc.2024.107540. Epub ahead of print. PMID: 38971316. 12: Park BS, Jeon H, Kim Y, Kwon H, Choi GE, Chi SG, Park HM, Lee H, Kim T. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma. Mol Cancer. 2024 Jul 4;23(1):136. doi: 10.1186/s12943-024-02031-w. PMID: 38965534; PMCID: PMC11223307. 13: Yoshisada R, Weller S, Çobanoğlu TS, de Kock HN, Jongkees SAK. Chemical Stability of mRNA/cDNA Complexes: Defining the Limits of mRNA display. Chem Asian J. 2024 Jul 2:e202400336. doi: 10.1002/asia.202400336. Epub ahead of print. PMID: 38953335. 14: Mundra S, Kabra A. Unveiling the Druggable Landscape of Bacterial Peptidyl tRNA Hydrolase: Insights into Structure, Function, and Therapeutic Potential. Biomolecules. 2024 Jun 7;14(6):668. doi: 10.3390/biom14060668. PMID: 38927071; PMCID: PMC11202043. 15: Singh R, Jiang R, Williams J, Dobariya P, Hanak F, Xie J, Rothwell PE, Vince R, More SS. Modulation of endogenous opioid signaling by inhibitors of puromycin-sensitive aminopeptidase. Eur J Med Chem. 2024 Sep 5;275:116604. doi: 10.1016/j.ejmech.2024.116604. Epub 2024 Jun 17. PMID: 38917665; PMCID: PMC11236497. 16: Subramanian B, Williams S, Karp S, Hennino MF, Jacas S, Lee M, Riella CV, Alper SL, Higgs HN, Pollak MR. Missense Mutant Gain-of-Function Causes Inverted Formin 2 (INF2)-Related Focal Segmental Glomerulosclerosis (FSGS). bioRxiv [Preprint]. 2024 Jun 10:2024.06.08.598088. doi: 10.1101/2024.06.08.598088. PMID: 38915495; PMCID: PMC11195136. 17: Tang YW, Jiang MY, Cao JW, Wan F. Triptolide decreases podocytes permeability by regulating TET2-mediated hydroxymethylation of ZO-1. Exp Biol Med (Maywood). 2024 May 31;249:10051. doi: 10.3389/ebm.2024.10051. PMID: 38881848; PMCID: PMC11176508. 18: Yuan Y, Wu Y, He M, Jiang X. Astragaloside IV Protects Against Podocyte Injury by Upregulating Mitophagy via the Mfn2/Pink1/Parkin Axis. Curr Mol Med. 2024 Jun 11. doi: 10.2174/0115665240310818240531080353. Epub ahead of print. PMID: 38867537. 19: McLellan JL, Morales-Hernandez B, Saeger S, Hanson KK. A high content imaging assay for identification of specific inhibitors of native Plasmodium liver stage protein synthesis. bioRxiv [Preprint]. 2024 May 29:2024.05.29.596519. doi: 10.1101/2024.05.29.596519. PMID: 38854116; PMCID: PMC11160711. 20: Wu Y, Zhang H, Wang Y, Zhang Y, Hong Z, Wang D. Sephin1 enhances integrated stress response and autophagy to alleviate myocardial ischemia-reperfusion injury in mice. Biomed Pharmacother. 2024 Jul;176:116869. doi: 10.1016/j.biopha.2024.116869. Epub 2024 Jun 7. PMID: 38850665.

View History

ICI-M247496

MedKoo CAT#: 576492

CAS#: 101248-32-2